Enterprise Value
2.792B
Cash
451.7M
Avg Qtr Burn
-49.34M
Short % of Float
5.87%
Insider Ownership
4.96%
Institutional Own.
70.74%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ARO-APOC3 Details Severe hypertriglyceridemia, Familial chylomicronemia syndrome | Phase 3 Data readout | |
Fazirsiran (ARO-AAT) (TAK-999) Details Severe alpha-1 antitrypsin deficiency, Liver disease | Phase 3 Update | |
ARO-ANG3 Details Dyslipidemia | Phase 2b Interim update | |
ARO-ANG3 Details Dyslipidemia | Phase 2 Update | |
ARO-C3 (RNAi) Details Paroxysmal nocturnal hemoglobinuria , Renal disease | Phase 1/2 Interim update | |
ARO-MUC5AC Details Lung disease, Muco-Obstructive Lung Diseases | Phase 1/2 Update | |
ARO-MMP7 Details Idiopathic pulmonary fibrosis | Phase 1/2 Update | |
ARO-RAGE Details Muco-Obstructive Lung Diseases, Asthma, Inflammatory disease | Phase 1/2 Update | |
ARO-DUX4 Details Facioscapulohumeral muscular dystrophy | Phase 1/2 Initiation | |
ARO-HSD Details Liver disease, Non-alcoholic steatohepatitis | Failed Discontinued | |
JNJ-3989 (ARO-HBV) Details Hepatitis B | Failed Discontinued |